Post-Ibrutinib Colitis and Intestinal Microbiota (COLMI)

Nantes University Hospital (NUH)

Status: Unknown

Conditions: Gastrointestinal Microbiome

Study type: Observational

Funder types: Other

Identifiers

NCT03569137

RC17_0463

Details and patient eligibility

About

Identify gut microbiome biomarkers associated with colitis in patients treated with targeted therapy in hematology

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years
• Outside the context of guardianship, -affiliated to the Social Security Regime and
• Having consented to participate in the COLMI study.
• Patient who benefit of treatment by targeted therapy to Ibrutinib

Exclusion criteria

• History of uncontrolled colitis before the start of treatment.
• Patient with inflammatory bowel disease.
• Patient not consenting to participate.